Cargando…
AB139. Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of non-muscle invasive bladder cancer
OBJECTIVE: To investigate whether low-dose BCG treatment can reduce the side effects while maintaining efficacy for patients with NMIBC when compared with standard dose BCG treatment. METHODS: A comprehensive literature search of PubMed, EMBASE, CINAHL, LILACS and CENTRAL databases was conducted to...
Autor principal: | Xu, Chuanliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842734/ http://dx.doi.org/10.21037/tau.2016.s139 |
Ejemplares similares
-
AB152. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016) -
Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Shuxiong, et al.
Publicado: (2015) -
AB066. The diagnostic value of narrow-band imaging for flat bladder lesions
por: Chang, Yifan, et al.
Publicado: (2018) -
AB095. Transurethral holmium laser bladder tumor submucosal dissection (HoL-BTSD) for non-muscle invasive bladder cancer
por: Weiguang, Liu, et al.
Publicado: (2018) -
AB175. Girdin protein is a novel prognosis predictor for patients with non-muscle invasive bladder cancer
por: Wu, Zhouliang, et al.
Publicado: (2016)